BrainChip Holdings Ltd – Recent Corporate Actions and Capital Structure Changes
Date of Publication: 3 April 2026
1. New Equity Issue and Capital Structure Update
On 31 March 2026, BrainChip Holdings Ltd (ASX: BRN) announced a capital increase involving the issuance of approximately 23 million new ordinary shares. The primary purpose of the increase is to provide financial flexibility while the company continues to commercialise its neuromorphic technology built on the Akida‑2.0 platform.
- Allocation of Shares
- 13 million shares are earmarked for LDA Capital under a pre‑existing put‑option agreement.
- 10 million shares will be allocated to the trustee of the company‑sponsored employee participation plan.
- 73 334 shares were issued following the vesting of Restricted Stock Units (RSUs) held by employees.
The total number of shares issued is expected to be 3,826,673 as per the ASX 3G notification dated 28 February 2026, with an additional 100,000 shares issued on 12 January 2026.
2. Unquoted Securities and Cessation Notices
Alongside the ordinary share issuances, BrainChip disclosed several movements concerning unquoted equity instruments:
| Security | Type | Status | Date |
|---|---|---|---|
| BRNAJ Performance Rights | Performance rights | Lapsed | 28 Feb 2026 |
| BRNAD Options | Stock options | Expires | 28 Feb 2026 |
| BRNAM Restricted Stock Units | RSUs | Lapsed | 28 Feb 2026 |
These cessations were reported under ASX Appendix 3H on 2 April 2026.
3. Upcoming General Meeting – Potential Board Change
The company’s annual general meeting (AGM) is scheduled for 6 May 2026 and will be conducted as a hybrid event in Sydney. Eight resolutions will be on the ballot, including:
- Re‑election of directors.
- Approval of the remuneration report.
- Resolution 8 – a clause that will trigger a board change if at least 25 % of votes cast are against the remuneration report.
Stakeholders should note that the AGM could lead to a shift in the board composition, depending on the outcome of Resolution 8.
4. Financial Snapshot (as of 1 April 2026)
| Item | Value |
|---|---|
| Close Price | AUD 0.145 |
| 52‑Week High (20 Apr 2025) | AUD 7.11 |
| 52‑Week Low (22 Mar 2026) | AUD 0.125 |
| Market Capitalisation | AUD 341 370 000 |
| Price‑to‑Earnings Ratio | –10.61 |
BrainChip’s valuation remains highly volatile, reflected in the wide 52‑week range and a negative P/E ratio.
5. Summary
BrainChip Holdings Ltd has undertaken a substantial equity issuance to strengthen its capital base while progressing the commercialisation of its Akida‑2.0 neuromorphic platform. Concurrently, the company is winding down several unquoted equity instruments and is preparing for a potentially consequential AGM that may alter its board structure. Investors should monitor the outcomes of the AGM and the performance of the newly issued shares for further insight into the company’s strategic direction.
